ASPOXICILLIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H27N5O7S
Molecular Weight	493.533
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)[C@H](N)CC(=O)NC)C3=CC=C(O)C=C3)C(O)=O

InChI

InChIKey=BHELIUBJHYAEDK-OAIUPTLZSA-N

InChI=1S/C21H27N5O7S/c1-21(2)15(20(32)33)26-18(31)14(19(26)34-21)25-17(30)13(9-4-6-10(27)7-5-9)24-16(29)11(22)8-12(28)23-3/h4-7,11,13-15,19,27H,8,22H2,1-3H3,(H,23,28)(H,24,29)(H,25,30)(H,32,33)/t11-,13-,14-,15+,19-/m1/s1

HIDE SMILES / InChI

Description
Sources: DOI: 10.1016/S0065-7743(08)60861-1
Curator's Comment: description was created based on several sources, including: http://www.drugfuture.com/chemdata/ASPOXICILLIN.html http://www.120ty.net/bencandy.php?fid=232&id=36758 http://www.229877.com/article/2012/1209/31983.html

Aspoxicillin is an injectable, amino acid-type penicillin highly active against Gram-positive ad Gram-negative bacteria, including the beta-lactamase producing Bacillus fragilis. It is reportedly effective in the treatment of peritonitis, pneumonia and bronchitis. Adverse reactions are: rash, urticaria, skin itching, vomiting, abdominal pain.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 233 Target ID: CHEMBL2354204 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3043036 \| http://www.ncbi.nlm.nih.gov/pubmed/10817702	Binding Agent 1064

Conditions

Condition	Modality	Highest Phase	Product
Peritonitis 22 Sources: http://www.229877.com/article/2012/1209/31983.html DOI: 10.1016/S0065-7743(08)60861-1	Curative	Approved 8429	Doyle Approved Use It is reportedly effective in the treatment of peritonitis
Pneumonia 90 Sources: DOI: 10.1016/S0065-7743(08)60861-1 http://www.229877.com/article/2012/1209/31983.html	Curative	Approved 8429	Doyle Approved Use It is used for treatment of pneumonia
Bronchitis 51 Sources: DOI: 10.1016/S0065-7743(08)60861-1 http://www.229877.com/article/2012/1209/31983.html	Curative	Approved 8429	Doyle Approved Use It is used for treatment of chronic and acute bronchitis

PubMed

Title	Date	PubMed
Aspoxicillin versus piperacillin in severe abdominal infections--a comparative phase III study.	1994 Nov	7706179
Morphological changes and lysis induced by beta-lactams associated with the characteristic profiles of affinities of penicillin-binding proteins in actinobacillus pleuropneumoniae.	2000 Jun	10817702
Antimicrobial susceptibility of Pasteurella multocida isolated from cattle and pigs.	2001 Sep	11666039
Comparative in vitro activity of 16 antimicrobial agents against Actinobacillus pleuropneumoniae.	2002 Jan	11860083

Patents

Sample Use Guides

In Vivo Use Guide

1-2 g twice a day, in severe infections – 6-8 g per day

Route of Administration: Intravenous

In Vitro Use Guide

The MIC90 values of aspoxicillin was 0.05 ug/ml for Actinobacillus pleuropneumoniae.

Name

Type

Language

ASPOXICILLIN

Official Name

English

ASPOXICILLIN [MI]

Common Name

English

ASPOXICILLIN [MART.]

Common Name

English

aspoxicillin [INN]

Common Name

English

DOYLE

Brand Name

English

(2S,5R,6R)-6-((2R)-2-((2R)-2-AMINO-3-(METHYLCARBAMOYL)PROPIONAMIDO)-2-(P-HYDROXYPHENYL)ACETAMIDO)-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID

Common Name

English

Aspoxicillin [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ01CA19